Hikma Pharmaceuticals PLC (HIK) · 2026-11-05
Hikma Pharmaceuticals said year-to-date Group performance was in line with its expectations, while 2026 Group revenue growth is expected at 2%–4% and Group operating profit at $740m–$760m, narrowed from $720m–$770m. Branded guidance has improved, but Injectables revenue is now expected to be broadly flat rather than grow.
Hikma Pharmaceuticals PLC (HIK) · 2026-08-06
Hikma Pharmaceuticals H1 revenue rose 4% and core operating profit 9%, while reiterating 2026 revenue growth guidance of 2% to 4% in constant currency.
Hikma Pharmaceuticals PLC (HIK) · 2026-08-06
Hikma Pharmaceuticals appoints Tobias Hestler as an independent non-executive director from 7 August 2026. He will join the Audit, Remuneration and Nomination and Governance Committees and is due to become Audit Committee chair after the 2027 AGM.